[EN] GOLD COMPOUNDS AND THEIR USE IN THERAPY<br/>[FR] COMPOSÉS D'OR ET LEUR UTILISATION DANS LE CADRE D'UNE THÉRAPIE
申请人:AUSPHERIX LTD
公开号:WO2018220171A1
公开(公告)日:2018-12-06
Compound of formula (I) and pharmaceutically acceptable salts and solvates thereof are described, wherein: Px selected from (P1), (P2) or (P3); The compounds are useful in the prevention or treatment of a bacterial infection.
[EN] TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF<br/>[FR] INHIBITEURS DE TOPOISOMÉRASE DE TYPE II ET PROCÉDÉS DE PRODUCTION ET D'UTILISATION DE CES DERNIERS
申请人:OHIO STATE INNOVATION FOUNDATION
公开号:WO2018195098A1
公开(公告)日:2018-10-25
Disclosed are Type II Topoisomerase Inhibitors, analogs thereof, pharmaceutical compositions thereof, and methods of making and using these compounds and compositions. Methods of using the disclosed compounds to treat infections, such as MRSA, MDR P. aeruginosa, and other pathogens are also described.
披露了II型拓扑异构酶抑制剂及其类似物、药物组合物以及制备和使用这些化合物和组合物的方法。还描述了利用所披露的化合物治疗感染,如MRSA、MDR P. aeruginosa和其他病原体的方法。
[EN] ALKYNYL PHOSPHINE GOLD COMPLEXES FOR TREATING BACTERIAL INFECTIONS<br/>[FR] COMPLEXE ALCYNYLPHOSPHINE-OR POUR TRAITER LES INFECTIONS BACTÉRIENNES
申请人:AUSPHERIX LTD
公开号:WO2017093544A1
公开(公告)日:2017-06-08
A compound of formula (I) for use in the prevention or treatment of a bacterial infection.
一种化合物,其化学式为(I),用于预防或治疗细菌感染。
[EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
申请人:AQUESTIVE THERAPEUTICS INC
公开号:WO2021087359A1
公开(公告)日:2021-05-06
Pharmaceutical compositions include a prodrug of epinephrine are described.
药物组合物包括表述的肾上腺素前药。
Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
申请人:Rogers D. Robin
公开号:US20070093462A1
公开(公告)日:2007-04-26
Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.